drugset / Trial / NCT01082640

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

NCT01082640

Phase 2 Completed 96 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.

Timeline

Start
2010-04
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Febuxostat Small molecule 30 mg Oral
Subject Febuxostat Small molecule 40 mg Oral
Subject Febuxostat Small molecule 80 mg Oral